The Patent Finder

Terms ending in 2039

BioAtla Inc.

Every in-force patent on BioAtla Inc.'s record whose computed term ends in 2039, whoever holds it now. Soonest term end first, then patent number.
PatentTitleHolderStatusExpiresConfidence
US 11,834,472Anti-Il-22 Antibodies, Antibody Fragments,Their Immunoconjugates And Uses Thereof
In force
 · High confidence
BioAtla, Inc.In forceHigh confidence
US 11,542,332ANTI-CTLA4 Antibodies, Antibody Fragments, Their Immunoconjugates and Uses Thereof
In force
 · High confidence
BioAtla, Inc.In forceHigh confidence
US 12,649,793ANTI-CTLA4 Antibodies, Antibody Fragments, Their Immunoconjugates and Uses Thereof
In force
 · Low confidence
BioAtla, Inc.In forceLow confidence
US 11,413,340Mesothelin Chimeric Antigen Receptor (CAR) and Antibody Against PD-L1 Inhibitor for Combined Use in Anticancer Therapy
In force
 · High confidence
President and Fellows of Harvard CollegeIn forceHigh confidence
4 of 4 patents shown. Soonest term end first, then patent number.
3 of these are in force and held by BioAtla Inc..
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited